Drug | MDCKII-MOCK | MDCKII-BCRP | ||||||
---|---|---|---|---|---|---|---|---|
EC50, −FTC (range) | EC50, +FTC (range) | N | RR | EC50, −FTC (range) | EC50, +FTC (range) | N | RR | |
µM | µM | µM | µM | |||||
Cytotoxic | ||||||||
Antimetabolites | ||||||||
Capecitabine | >200 (–) | >200 (–) | 1 | NC | >200 (–) | >200 (–) | 1 | NC |
Methotrexate | 0.035 (–) | 0.028 (–) | 1 | 1.3 | 0.047 (–) | 0.026 (–) | 1 | 1.8 |
Topoisomerase I inhibitor | ||||||||
SN-38 | 0.16 (0.14–0.17) | 0.051 (0.044–0.057) | 2 | 3.1 | 6.5 (6.4–6.6) | 0.070 (0.069–0.070) | 2 | 94 |
Topotecan | 0.39 (0.31–0.46) | 0.26 (0.19–0.33) | 2 | 1.5 | 14 (12–16) | 0.44 (0.36–0.52) | 2 | 32 |
Topoisomerase II inhibitor | ||||||||
Mitoxantrone | 0.29 (0.29–0.29) | 0.26 (0.26–0.26) | 2 | 1.1 | 1.2 (1.1–1.3) | 0.29 (0.28–0.30) | 3 | 4.0 |
Etoposide | 2.8 (–) | 1.8 (–) | 1 | 1.6 | 5.2 (–) | 2.1 (–) | 1 | 2.5 |
Teniposide | 0.57 (–) | 0.42 (–) | 1 | 1.4 | 1.4 (–) | 0.47 (–) | 1 | 3.0 |
Molecular targeted | ||||||||
Cyclin-dependent kinase inhibitor | ||||||||
Dinaciclib | 0.065 (–) | 0.030 (–) | 1 | 2.2 | 0.18 (–) | 0.027 (–) | 1 | 6.7 |
Flavopiridol | 0.12 (0.12–0.12) | 0.12 (0.11–0.12) | 2 | 1.0 | 0.54 (0.46–0.61) | 0.097 (0.084–0.11) | 2 | 5.5 |
NC, not calculated.